Material
+ Tregs and plays a central role in establishing and maintaining the Treg lineage. Deficiency of a functional Foxp3 gene in both humans and mice leads to ablation of Tregs, severe autoimmunity, and early mortality (1, 2) . Therefore, elucidating the factors that control Foxp3 expression will advance our understanding of Treg biology and its therapeutic application for immune diseases.
IL-2 has long been considered a major T cell growth factor optimizing immune responses, as signaling through its high-affinity IL-2R (consisting of the IL-2Ra [CD25], IL-2Rb, and common g-chain [gc] subunits) is essential for the expansion of recently activated effector T (Teff) cells (3) . Therefore, it was somewhat unexpected that mice deficient in IL-2, IL-2Ra, or IL-2Rb developed autoimmune diseases, often with lethal consequences (4, 5) . Further studies revealed that Tregs constantly express highaffinity IL-2R. Indeed, because a constant supply of IL-2 is critical for Treg homeostasis, the lethal autoimmunity was eventually associated with an IL-2 signaling defect in Tregs (3, 6) . Thus, IL-2 proved to be an essential cytokine not only in Teff-mediated immunity but also in Treg-maintained immune tolerance (3, 7) . Studies by our group and others have further shown that Tregs exert their suppressive effect on Teff cell responses at least partially through creating and modulating an IL-2-deprived environment (8, 9) .
Foxp3-expressing Tregs are either derived from the thymus as natural regulatory T cells (nTregs) or generated de novo from peripheral mature CD4 +
Foxp3
2 T cells in response to TCR stimulations as adaptive, or inducible, regulatory T cells (iTregs) (10) . The low frequency of CD4 + CD25 + Foxp3 + cells in the thymus of IL-2Rb 2/2 mice led to the assumption that IL-2 signaling is also critical for thymic nTreg generation (6) . Moreover, mice deficient in both IL-2 and IL-15 (also binding to IL-2Rb) exhibit marked deficiency in thymic nTregs (11) . Recently, a "two-step model" of thymic nTreg generation suggested that TCR-ligand interactions result in elevated CD25 (IL-2Ra) expression on Foxp3 -CD4 single positive (CD4SP) thymocytes, followed by an IL-2-directed and TCR-independent step that subsequently induces Foxp3 expression in these CD25 +
-CD4SP nTreg precursors (12, 13) . Some other gc-dependent cytokines (IL-7 and IL-15) less effectively induced Foxp3 expression in nTreg precursors (14) .
The essential polarizing cytokines involved in the differentiation of iTregs appear to be TGF-b and IL-2. In vitro activation of CD4 +
CD25
2 Foxp3 2 T cells in the presence of exogenous TGF-b results in a substantial percentage of Foxp3-expressing iTregs (15) . Importantly, IL-2 was required for TGF-b-mediated iTreg differentiation, as addition of IL-2 neutralizing Ab to cultures or using IL-2-deficient T cells abrogated iTreg generation induced by exogenous TGF-b. In addition, only IL-2, but not other gc cytokines, was able to restore TGF-b-mediated Foxp3 expression in IL-2-deficient T cells (16, 17 
Materials and Methods
), B6.129S7-Rag1tm1Mom/J (Rag1 2/2 ), B6.Cg-Foxp3tm2Tch/J (Foxp3/GFP), and B6.Cg-Tg(Cd4-TGFBR2)16Flv/J (dnTGFBRII) mice were purchased from The Jackson laboratory (Bar Harbor, ME). B6.SJL-Ptprca/BoyAiTac (B6.SJL) congenic mice were obtained from Taconic Farms (Hudson, NY). Animals were maintained at the University of Toledo specific pathogen-free animal facility according to institutional guidelines.
Abs, cytokines, and reagents
Fluorescence-conjugated Abs were purchased from BD Biosciences and eBioscience. Purified anti-CD3 and anti-CD28 mAbs, BD Phosflow Lyse/ Fix Buffer I, BD Phosflow Perm/Wash Buffer I, and FITC Annexin V Apoptosis Detection Kit were purchased from BD Biosciences. Functionalgrade anti-IL-2 mAbs (clone S4B6 or JES6), anti-CD25 (PC61) mAb, and anti-Foxp3-PE and intracellular staining kit were purchased from eBioscience. CFSE was obtained from Molecular Probes. TGF-b neutralizing Abs (9016 or 1D11), murine recombinant thymic stromal lymphopoietin, and IL-7 were purchased from R&D Systems. Other murine recombinant cytokines were purchased from Peprotech. An inhibitor of TGF-b superfamily type I activin receptor-like kinase receptors (SB-431542) was purchased from Sigma-Aldrich. Jak3 inhibitor (CP690550) was purchased from Axon Biochemicals BV, whereas the Stat5 inhibitor [N9-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide] and the Stat3 inhibitor (WP1066) were obtained from EMD Bioscience. Abs specific for Smad3 (C67H9) and phospho-Smad3 (C25A9) were purchased from Cell Signaling Technology. Anti-b-actin and lumin B mAbs were obtained from BD Biosciences and Santa Cruz Biotechnology, respectively.
Cell preparation, cultures, and flow cytometry 
CD25
-splenocytes from different mice were cultured in 96-well flat-bottom plates, and were stimulated with 4 mg/ml plate-bound anti-CD3 mAb and 2 mg/ml soluble anti-CD28 mAb for 3 d. During this TCR-directed conditioning phase, 10 mg/ml anti-IL-2 mAb, 10 mg/ml anti-CD25 mAb, 5 mg/ml anti-TGF-b mAb, 1 mM TGF-b inhibitor, 50 nM JAK3 inhibitor, 150 mM STAT3 inhibitor, 50 mM STAT5 inhibitor, or 2 ng/ml TGF-b was added into the cultures, respectively. The cells were then washed and cultured again, this time in the presence of 10 U/ml IL-2 or 10 ng/ml other cytokines for 3 d (the Foxp3-induction phase 
-B6 splenocytes stimulated with 4 mg/ml plate-bound anti-CD3 mAb and 2 mg/ml soluble anti-CD28 mAb were cultured in the presence or absence of anti-IL-2 mAb (JES6, 10 mg/ml), JAK3 inhibitor (CP690550, 50 nM), or STAT5 inhibitor (50 mM). After 3-d activation, the levels of TGF-b and IL-2 in culture supernatants were assessed by ELISA, using commercial kits according to the manufacturer's instructions (R&D Systems).
Western blot analysis

CD4
+ CD25 -B6 splenocytes stimulated by 4 mg/ml plate-bound anti-CD3 mAb and 2 mg/ml soluble anti-CD28 mAb were cultured in the presence or absence of anti-IL-2 mAb (JES6, 10 mg/ml) or TGF-b (2 ng/ml). Nuclear and cytoplasmic extracts were prepared from 3-d cultured cells, using a commercial lysis buffer (NE-PER Nuclear and Cytoplasmic Extraction Reagents; Thermo Fisher Scientific). Protein concentration was determined by Bradford assay using the Coomassie Protein Assay Reagent (Pierce) and a Bio-Rad spectrophotometer. Equal amounts of protein (30 mg) were loaded in each lane and separated by SDS-polyacrylamide gel (10%) electrophoresis. Fractionated proteins were blotted onto a nitrocellulose membrane (Bio-Rad). Blots were probed with anti-Smad3 (C67H9) rabbit mAb, followed by HRP-labeled goat anti-rabbit IgG (Santa Cruz Biotechnology), and visualized by SuperSignal West Pico Chemiluminescent Substrate (Pierce) and the FluorChem 890 Alpha Innotech) detection system. To detect the phospho-Smad3 expression, the probed membrane was stripped (2% SDS, 62.5 mM Tris-HCl, 100 mM 2-ME, and pH adjusted to 6.5) and reprobed with Phospho-Smad3 (Ser 
Induction and prevention of colitis
Single-cell suspensions were obtained from spleen and mesenteric lymph node of B6 mice, and were labeled with anti-CD45RB-FITC, anti-CD25-PE, and anti-CD4-PE-Cy5. CD4 2/2 mouse. Some RAG1 2/2 mice were also injected with 4 3 10 5 CD4 + CD45RB low CD25 + nTregs or CP-iTregs. Mice were monitored weekly for body weight and were euthanized 8 wk after T cell transfer. Cecum, proximal colon, midcolon, and distal colon were removed and fixed in 10% buffered formalin, paraffin-embedded, sectioned, and stained with H&E. Inflammation was scored in a blinded fashion, using a previously described scoring system (19) .
Statistical analysis
Statistical analysis was performed using an unpaired, two-tailed, Student t test to calculate p values. Calculated p , 0.05 was considered statistically significant. 
Results
IL-2 induces
IL-2 deprivation upon TCR stimulation generates iTreg precursors
To further reveal the mechanism of iTreg differentiation, we established a two-step method to delineate the conditions for the formation of iTreg precursors ( Fig. 2A) . In the initial "conditioning" step, CD4 + CD25 2 Foxp3/GFP 2 splenocytes isolated from Foxp3/ GFP mice were stimulated with plate-bound anti-CD3 mAb and soluble anti-CD28 mAb, and exposed to various cytokines, mAbs, and inhibitors. At 3 d later, cells were washed and rested with IL-2 (10 U/ml) for an additional 3 d; this served as the "Foxp3-induction" step to determine the presence of putative iTreg precursors after conditioning ( Fig. 2A) .
To assess the role of IL-2 in generating iTreg precursors, we added exogenous IL-2 or anti-IL-2 neutralizing mAbs during the initial conditioning step. As shown in Fig. 2B and 2D, few Foxp3/ GFP + cells could be detected in the 6-d culture of CD4 + CD25 2 Foxp3/GFP 2 splenocytes, which were treated with or without exogenous IL-2 during conditioning. In contrast, neutralizing IL-2, by addition of an anti-IL-2 mAb (clone S4B6 or JES6) during an initial 3-d conditioning step followed by an IL-2-driven Foxp3 induction step, resulted in a high frequency (40%) of Foxp3/GFP + cells (Fig. 2C, 2D ). The Foxp3/GFP expression was induced during the IL-2-driven Foxp3-induction step (days 4 to 6), as very few Foxp3/GFP + cells could be detected after 3-d conditioning by neutralizing IL-2 (Supplemental Fig. 1) . The results from these experiments suggest that an initial IL-2 deprivation upon TCR stimulation generates iTreg precursors, which then express Foxp3 upon subsequent exposure to IL-2.
To confirm the above finding, IL-2 2/2 CD4 + CD25 2 T cells were labeled with CFSE and cultured using the same two-step method. After 6 d of culture, the Foxp3 expression was assessed by intracellular staining. To exclude many IL-2 2/2 T cells that were not activated and that were not proliferating, the flow cytometric analysis of cultured cells was gated only on dividing cells based on the CFSE dye dilution. As shown in Fig. 2E The IL-2Rabg complex associates with the intracellular tyrosine kinases: Jak1, which binds to the IL-2Rb-chain, and Jak3, which binds to the IL-2Rg-chain. Binding of IL-2 to high-affinity IL-2R results in autophosphorylation and activation of Jak1 and Jak3. We used an anti-IL-2 mAb (clone S4B6 or JES6), an anti-CD25 (IL2Ra) mAb (clone PC61), or a Jak3 inhibitor (CP690550) to define the role of IL-2 signaling in the formation of iTreg precursors. CD4 + CD25 2 Foxp3/GFP 2 splenocytes isolated from Foxp3/GFP mice were cultured using the two-step method described in Fig. 2A . Addition of anti-IL-2 mAb, anti-CD25 mAb, or CP690550 during the conditioning step did not induce Foxp3-expressing cells in 3-d cultures (Supplemental Fig. 1 ). However, subsequent exposure of these cells to 10 U/ml IL-2 resulted in an increase in Foxp3/GFP + cells to 30-50% in the 6-d cultures (Fig.  3A, 3C) . Thus, initial blockade of IL-2 signaling by different methods upon TCR stimulation generates iTreg precursors, which in turn express Foxp3 upon IL-2 exposure.
During the TCR-directed conditioning step, anti-IL-2 mAb, anti-CD25 mAb, or CP690550 only marginally downregulated the phosphorylation of Stat5 Y694 (Supplemental Fig. 2A ). Moreover, in contrast to 250 mM Stat5 inhibitor, 50 mM Stat5 inhibitor did not decrease the phosphorylation of Stat5 Y694 (Supplemental Fig.  2B ). However, addition of 50 mM Stat5 inhibitor (but not Stat3 inhibitor) during the conditioning step was sufficient to generate 30-50% Foxp3/GFP + cells in the 6-d culture of CD4 + CD25 2 Foxp3/GFP 2 cells (Fig. 3B, 3C ). Further studies are required to define how Stat5 and other transcription factors influence the programming of iTreg precursors. We also investigated the effects of cytokines on the second Foxp3-induction step (Fig. 3D) . Following an initial 3-d conditioning step of CD4 + CD25 2 Foxp3/GFP 2 cells with Jak3 inhibitor (CP690550), the culture was washed and supplemented with 12 different cytokines. As shown in Fig. 3D , IL-2 alone was the most
The Journal of Immunologypotent cytokine for inducing Foxp3, whereas IL-7 and IL-15 were much less effective and other cytokines were not effective; IL-4 inhibited Foxp3 expression. Various concentrations of plate-bound anti-CD3 mAb and soluble anti-CD28 mAb were also investigated in the two-step generation of iTregs. As shown in Fig. 3E , in the presence of CP690550 during the conditioning step, 4 mg/ml anti-CD3 mAb induced more iTregs than 0.5 mg/ml anti-CD3 mAb (Fig. 3Eii) . Thus, proper TCR stimulation is required to induce iTregs in this system. In the absence of CP690550 conditioning, none of the anti-CD3/ CD28 mAb concentrations used was able to generate iTregs. Thus, conditioning of naive T cells by TCR stimulation and IL-2 signaling blockade transforms them into iTreg precursors, which are robustly induced by IL-2 to become Foxp3-expressing iTregs.
Characterization of CD4 + T cells during iTreg generation
By CFSE labeling of CD4 + CD25 2 cells prior to cultivation, using the two-step method, we showed that a significant cell proliferation was retained in cultures from day 2 to day 6 (Fig. 4A) , regardless of the conditioning treatment with 10 mg/ml anti-IL-2 mAb or 50 nM CP690550. Foxp3 expression in cells could not be significantly induced unless IL-2 was neutralized or IL-2 signaling was blocked during the initial conditioning step (Fig. 4A-C) . Addition of IL-2 into the conditioned cultures at day 3 then promptly induced Foxp3 expression within 12 h, and further enhanced the frequency (Fig. 4A, 4B ) and total number (Fig. 4C ) of Foxp3-expressing cells in the following 3 d. Thus, these two events must happen in sequence for an efficient induction of precursors and a timely switch to iTregs. Moreover, a similar frequency of Foxp3 + cells was detected in each divided cell population (Supplemental Fig. 3A, 3B ). It is possible that during the Foxp3 induction step, IL-2 upregulates Foxp3 expression equally in each dividing cell population. Significant cell proliferations were observed during iTreg generation (Fig. 4A) , suggesting that this two-step process did not inhibit T cell activation. Indeed, the evaluation of T cell activation markers CD25 and CD69 after stimulation of CD4 + CD25 2 wildtype T cells showed that T cell activation was not dramatically impaired by the conditioning treatment with 10 mg/ml anti-IL-2 mAb or 50 nM CP690550 (Fig. 4D) . During the conditioning step, 10 mg/ml anti-IL-2 mAb was sufficient to neutralize IL-2 in the 3-d cultures. Nevertheless, blocking IL-2 signaling with 50 nM Jak3 inhibitor or 50 mM Stat5 inhibitor reduced (but did not completely inhibit) IL-2 production (Supplemental Fig. 3C ). We also investigated the possible proapoptotic effect produced in the conditioning step. As shown in Supplemental Fig. 4A and 4B, the conditioning treatment with anti-IL-2 mAb, anti-CD25 mAb, or Jak3 inhibitor (CP690550) at the indicated concentrations did not affect the proliferation of cells during iTreg generation, and it did not increase the frequency of apoptotic cells (annexin V positive) in the cultures. In fact, TCR stimulation enhanced expression of the antiapoptotic molecule Bcl-2, and the conditioning treatment with 10 mg/ml anti-IL-2 mAb or 50 nM CP690550 did not inhibit Bcl-2 expression (Fig. 4E ). These results demonstrate that in response to TCR stimulation, CD4 + CD25 2 cells receiving diminished IL-2 signaling can be activated to proliferate, but their differentiation is directed into iTreg precursors. The described culture conditions do not diminish the survival of T cells despite the use of mAbs and inhibitors at the indicated concentrations.
Inhibition of TGF-b signaling upon TCR stimulation reduces iTreg differentiation
Addition of exogenous TGF-b during T cell activation potently upregulates Foxp3 expression in T cells. We did not add exogenous TGF-b to the cultures during the process of iTreg generation, and the TGF-b concentration in the cultures was low (between 40 and 55 pg/ml), as shown in Fig. 5A . Addition of 2 ng/ml exogenous TGF-b upon TCR stimulation increased the expression level of phosphorylated Smad3 both in the cytoplasmic fraction of T cells (Fig. 5B , left panel) and more predominantly in the nucleus (Fig. 5B, right panel) . In contrast, neutralizing IL-2 in the absence of exogenous TGF-b did not upregulate the expression of phosphorylated Smad3 in both locations (Fig. 5B) . Thus, enhanced TGF-b signaling via activation of Smads is dispensable for the IL-2 deprivation-mediated generation of iTreg precursors.
To test whether TGF-b signaling was required for the formation of iTreg precursors, CD4 + CD25 2 T cells were stimulated with anti-CD3/anti-CD28 mAbs in the presence of conditioning treat- (Fig. 5C, 5D ). Furthermore, we assessed iTreg differentiation using CD4 + CD25 2 splenocytes isolated from dnTGFbRII mice, which express a dominant-negative form of the human TGF-b receptor II under the direction of the mouse CD4 promoter. Again, only 5-7% of Foxp3-expressing cells were present in the 6-d cultures that received conditioning treatment with anti-IL-2 mAb, anti-CD25 mAb, or Jak3 inhibitor followed by exposure to IL-2 (Fig. 5E, 5F ). These results reveal that although significant TGF-b signaling via activation of Smads was not observed, the blockade of TGF-b signaling reduced IL-2 deprivation-mediated generation of iTreg precursors. We further investigated whether the levels of TGF-b signaling affect the two-step generation of iTregs. CD4 + CD25 2 T cells were stimulated with anti-CD3/anti-CD28 mAbs in the presence of conditioning treatment with 50 nM CP690550. At 3 d later, cells were washed and recultured with 10 U/ml IL-2. As shown in Fig.   5Gi , addition of anti-TGF-b mAb or TGF-b inhibitor during the CP690550-conditioning step inhibited iTreg generation. By contrast, addition of exogenous TGF-b during the conditioning step dose-dependently increased the iTreg generation and could induce ∼ 90% Foxp3 + cells in the day 6 cultures (Fig. 5Gi) . However, addition of exogenous TGF-b or blockade of TGF-b signaling during the IL-2-exposing step only mildly modulated the iTreg generation (Fig. 5Gii) . Therefore, TGF-b signaling promotes iTreg generation at the early stage after TCR stimulation.
Two-step-generated iTregs prevent experimental colitis
To characterize the phenotype and function of the CD4 + Foxp3 + iTregs generated under IL-2 signal deprivation conditions in response to TCR stimulation, we examined additional membrane and intracellular markers, the stability of Foxp3 expression, and the suppressive function of these cells. With our standard procedure, CD4 + CD25 -Foxp3/GFP -T cells were stimulated for 3 d with anti-CD3/anti-CD28 mAb in the presence of CP690550, followed by exposure to IL-2 for an additional 3 d. Flow cytometric analysis showed that these CP-iTregs in the 6-d cultures expressed high levels of CD25, GITR, and CTLA4 on their surface, a cell surface phenotype similar to that of ex vivo sorted CD4 + Foxp3/GFP + nTregs (Fig. 6A) . When evaluated by previously described methods (18, 21) , nTregs, but not CD4 + Foxp3/GFP + iTregs (generated with exogenous TGF-b; TGF-b-iTreg), stably maintained their Foxp3 expression upon repeated stimulation (Fig. 6B, left two panels) . Of interest, upon repeated TCR stimulation, 60-75% of the CD4 + Foxp3/GFP + iTregs obtained by our two-step culture conditions maintained their Foxp3 expression (Fig. 6B , right two panels, anti-IL-2-iTreg and CP-iTreg). Nevertheless, CP-iTregs expressed lower levels of Helios than did nTregs (Fig. 6Ci versus iii) . Helios expression was also low in TGF-b-iTregs (Fig. 6Cii) , ex vivo isolated CD4 + CD25 + Foxp3 -splenocytes (Fig. 6Civ) , and Foxp3 + cells generated from the cultures of ex vivo isolated CD4 + CD25 + Foxp3 -splenocytes after IL-2 exposure (Fig. 6Cv) .
To investigate the suppressive function of two-step-generated iTregs, we cultured nTregs or CP-iTregs together with CFSElabeled syngeneic CD4 + CD25 -T cells, which were stimulated by syngeneic APCs and soluble anti-CD3 mAb. We found that nTregs and CP-iTregs suppressed CD4 + CD25 -T cell proliferation in a similar fashion (Fig. 6D) . On the basis of these experiments, we concluded that IL-2 signal deprivation-conditioned CP-iTregs exhibit relatively stable expression of Foxp3 and exert suppressive function in vitro similar to that in nTregs, but remain different from nTregs in Helios expression.
To assess the in vivo suppressive function of CP-iTregs, we transferred sorted CD4 + CD45RB
high T cells alone, or together with either CP-iTregs or nTregs, into Rag1 2/2 mice. Host mice receiving CD4 + CD45RB high T cells alone dramatically lost body weight within 8 wk after cell transfer, whereas host mice receiving CD4 + CD45RB
high T cells, together with either CP-iTregs or nTregs, remained healthy without losing body weight (Fig. 6E) . The average histology scores of nTreg-or CP-iTreg-treated groups were similar and were indicative of a low degree of inflammation compared with scores of mice that did not receive Tregs (Fig. 6F, 6G) . Thus, CP-iTregs are suppressive in vivo, and prevent experimental colitis in mice.
Discussion
IL-2 is the principal T cell growth factor normally produced by Teff cells in response to antigenic stimulation. Binding of IL-2 to highaffinity IL-2R on Teff cells upon Ag stimulation positively regulates the magnitude and duration of Teff cell responses, and is even required for the generation of functional memory T cells (3, 22) . Nevertheless, IL-2 also plays a critical role in maintaining tolerance by controlling Treg homeostasis and function (3, 7) . In particular, IL-2 is the major growth factor for CD4 + CD25 + Foxp3 + Tregs. The lethal autoimmune phenotype observed in mice deficient in IL-2, IL-2Ra, or IL-2Rb is attributable to a Treg defect (4, 5) . Moreover, an IL-2:anti-IL-2 mAb complex has been shown to dramatically expand Tregs in vivo, and prevent experimental autoimmune encephalomyelitis as well as islet allograft rejection in mice by expanding Tregs (23, 24) . Low-dose IL-2 treatment also reverses the onset of type 1 diabetes in NOD mice through enhancing CD25 and Foxp3 expression in pancreatic Tregs, which may subsequently upregulate Treg function (25) . More profoundly, IL-2 is also involved in Treg generation, and induction of Foxp3 expression in CD25 
Foxp3
-T cells (12, 20) . Because Treg generation also requires TCR stimulation, we sought to understand how IL-2 signals during T cell priming influence different outcomes (e.g., generating Teff cell versus iTreg responses) in T cells.
In this study, we investigated the role of IL-2 signaling in iTreg generation, using a two-step differentiation model, which includes an initial TCR-driven conditioning step generating iTreg precursors and a subsequent cytokine-driven step inducing Foxp3 expression in those precursors. In the TCR-driven conditioning step, inhibition of IL-2 signaling via Jak3-Stat5 conditions naive CD4 IL-2 deficiency protects naive T cells from apoptosis by switching them to an iTreg precursor line, but their further development is dependent upon timely exposure to gc cytokines to induce Foxp3 expression.
Differentiation of naive T cells into various Teff cell subsets requires TCR stimulation and distinct polarizing cytokines. For iTreg differentiation, TGF-b appears to be the most potent polarizing cytokine (15, 26) . In most in vitro studies, high amounts of exogenous TGF-b (at the nanogram per milliliter level) are needed to convert TCR-stimulated naive CD4 + T cells into Foxp3-expressing iTregs (15, 18) . Such high amounts of TGF-b may be rare under physiological conditions. Moreover, in the presence of exogenous TGF-b (at the nanogram per milliliter level), addition of IL-2 during the initial TCR stimulation does not inhibit iTreg generation and even facilitates the generation of high frequencies of iTregs (16, 17) . Nevertheless, these TGF-b-iTregs promptly lose Foxp3 expression upon TCR restimulation (Fig. 6B) . We demonstrated in our two-step process of iTreg differentiation that exogenous TGF-b is not required, as the need for downstream Smad2/Smad3 signaling seemed to be minimal. However, a low level of TGF-b signaling is needed with a yet undefined TGF-b origin, as neutralizing TGF-b or blocking TGF-bR signals decreased iTreg generation. Addition of exogenous TGF-b during the conditioning step dose-dependently increased the iTreg generation and could induce ∼ 90% Foxp3 + cells in the day 6 cultures (Fig. 5Gi) . Therefore, two-step iTreg development is favored when environmental TGF-b levels are relatively high.
The transcription factor Stat5 is part of the downstream IL-2 signaling pathway. Activated Stat5 translocates to the nucleus and binds to the promoter region and an intronic regulatory DNA element within the Foxp3 locus (11, 27, 28) + CD45RB high T cells alone (Teff alone group; n = 5), or together with the same number of nTreg (Teff:nTreg group; n = 3) or CP-iTregs (Teff:CP-iTreg group; n = 5). The mice were monitored regularly for 8 wk and were then sacrificed to obtain colons for histological analysis. In (E), the % body weight change of mice from each group is shown. In (F), the bar graph shows the histology scores for Rag1 2/2 mice receiving CD4
findings of this paper do not contradict these previous reports, as IL-2/Stat5 signaling is needed to induce Foxp3 expression in iTreg precursors. However, the striking observation of our work reveals that TCR stimulation under a low IL-2/Stat5 signaling condition (i.e., IL-2-deficient T cells, IL-2 neutralizing mAb, IL-2Ra blocking mAb, as well as Jak3 or Stat5 inhibition) generates iTreg precursors. Recently, analyzing mice with a deletion of the Stat5a/ b amino termini or with a T cell-specific deletion of Stat5 showed that these mice have residual Stat5 function and thus have some Tregs (11, 27) , suggesting that a low Stat5 signaling threshold allows for the development of Treg precursors. Further studies should elucidate the delicate balance between the effects of Stat5 signaling on the generation of iTreg precursors and the differentiation into Teff cells. T cells produce IL-2 in response to TCR stimulation. We now show that this natural process not only optimizes Teff cell function but also restrains the formation of iTreg precursors. This finding implies that iTreg differentiation in vivo is limited under immunogenic Ag stimulation. Indeed, iTreg generation is generally identified under certain defined conditions, such as suboptimal Ag presentation and chronic low-dose exposure to Ags, and in unique environments, such as GALTs (10, 29) . In particular, Kretschmer et al. (30) have shown that the conversion of truly naive CD4 T cells into iTregs in vivo was achieved by minute Ag doses with suboptimal dendritic cell activation. More strikingly, in the same host, adoptively transferred IL-2 2/2 T cells converted into iTregs 2-to 3-fold more efficiently than did IL-2-competent T cells (30) .
Our study likely provides an insight into the mechanism of their finding, as low IL-2/Stat5 signaling in IL-2 2/2 T cells during the TCR-directed conditioning step induces the formation of iTreg precursors, which may subsequently receive paracrine IL-2 from IL-2-competent T cells for Foxp3 induction. We thus speculate that when T cells receive suboptimal or chronic Ag stimulation in the absence of robust IL-2 signaling some of these cells develop into Treg precursors that then remain in the environment, where, over time, sufficient levels of environmental IL-2 for Foxp3 induction become available. This two-step iTreg generation still requires low levels of TGF-b and should be favored in unique environments where TGF-b levels are relatively high, such as GALTs (10, 29) . Compared with iTreg generation by TCR stimulation in the presence of high amounts of exogenous TGF-b (at the nanogram per milliliter level) and IL-2, our model may mimic and provide insights into the biological conditions favorable for iTreg generation, as high amounts of IL-2 and TGF-b (at the ng/ ml level) are not often present at the same time physiologically. In summary, IL-2/Stat5 signaling during TCR stimulation negatively regulates the formation of iTreg precursors, but positively regulates the subsequent Foxp3 expression in these precursors. The iTregs generated by our two-step method showed relatively stable Foxp3 expression upon TCR restimulation (in comparison with exogenous TGF-b-induced iTregs) and prevented CD4 + CD45RB
high cell-mediated colitis in Rag1 2/2 mice. Importantly, the number of generated iTregs in the 6-d culture was 5-fold more than the initial number of cultured naive T cells. These aspects of our two-step-generated iTregs may facilitate the clinical application of iTregs as a cell therapy for immune disorders.
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